# Shanghai LePure Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-lepure-biotech-co

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.lepure-bio.com
- Latest round: Series C (Jan 12, 2023)
- Investors on record: 11

## About

Established in 2011 and based in Shanghai, China, Shanghai LePure Biotech Co., Ltd., trading under the name Lepure, is a biology technology company that provides disposable products for the biotechnology and pharmaceutical industries. It has additional offices in Beijing, and the USA. As of January 2023, Lepore has more than 600 biopharmaceutical customers in China, and its products are exported to Peru, Singapore, and other countries. It also has a 10,000 square meters cleanroom, 700 employees, and more than 30 patents. In 2019, its product landed on the moon with Chang'e-4.

The company engages in the design, development, and manufacturing of single-use equipment and consumables for bioprocess applications. Products include storage and shipping bags, aseptic sealers and tubing for fluid,  mixing systems and mixing bags, cell cultivation and fermentation equipment, filtration and purification equipment, and filling equipment. Those products are used for the storage, transfer, filling and leak detection of various samples in biosimilars, vaccines and other biopharmaceutical processes. At the same time, the company provides biopharmaceutical companies such as antibodies, vaccines, and cell and gene therapy with process solutions for the entire life cycle from drug research and development, and pilot trials to commercial production.

## Funding rounds

- Series C, Jan 12, 2023 — General Atlantic, Novo Holdings, Goldman Sachs Asset Management, HighLight Capital, China Science and Tech Innovation Venture Capital, HM Capital, Kangjun Capital
- Series B, Nov 1, 2021 — Legend Capital, Hillhouse Investment, TMT Investments, New Alliance Capital, HM Capital

## Investors

- Legend Capital — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- TMT Investments (https://capitalatlas.ai/funds/tmt-investments) — Series B
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B, Series C
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series C
- Novo Holdings — Series C
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series C
- China Science and Tech Innovation Venture Capital (https://capitalatlas.ai/funds/china-science-and-tech-innovation-venture-capital) — Series C
- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series C